Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?

被引:1
作者
Elsayed, Marwa [1 ]
Harry, Stephanie [2 ]
Nanua, Suprana [3 ]
Zaidi, Shayaan [4 ]
Habib, Muhammad H. [5 ]
Raza, Shahzad [3 ]
机构
[1] Univ Missouri Kansas City, Internal Med, Sch Med, Kansas City, MO USA
[2] St Francis Canc Ctr Warren Clin, Hematol Oncol, Tulsa, OK USA
[3] Univ Missouri Kansas City, St Lukes Canc Inst, Oncol, Kansas City, MO 64110 USA
[4] Univ Kansas, Sch Med, Oncol, Kansas City, MO USA
[5] Rutgers Canc Inst New Jersey, Oncol, New Brunswick, NJ USA
关键词
atypical chronic myeloid leukemia; chronic myeloid leukemia; myelodysplastic (mds); myeloproliferative neoplasm (mpn) disease spectrum; myelodysplastic; myeloproliferative diseases; trametinib; next-generation sequencing studies; atypical chronic myelogenous leukemia; CHRONIC MYELOMONOCYTIC LEUKEMIA; WORLD-HEALTH-ORGANIZATION; CHRONIC NEUTROPHILIC LEUKEMIA; SETBP1; MUTATIONS; RISK-FACTORS; THERAPY; CML; DECITABINE; TRANSPLANTATION; CLASSIFICATION;
D O I
10.7759/cureus.26619
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atypical chronic myeloid leukemia (aCML) is a rare disease that is currently classified under the myelodysplastic (MDS)/myeloproliferative neoplasm (MPN) disease spectrum. MDS/MPN diseases are characterized by the absence of the Philadelphia (Ph) chromosome and the overlap between bone marrow fibrosis and dysplastic features. The Ph chromosome, resulting from BCR-ABL1 translocation, helps to distinguish aCML from chronic myeloid leukemia (CML). The currently reported incidence of aCML is imprecise because aCML is diagnosed primarily based on morphological features and other unspecified laboratory findings, and there is an especially high chance of under-diagnosis of aCML and other MDS/MPN diseases. Recent advances in next-generation sequencing (NGS) have allowed a greater understanding of the nature of aCML, providing better opportunities to achieve higher diagnostic accuracy and for the use of more targeted treatment to achieve better outcomes. Herein, we present a case of a 68-year-old woman who came to our hospital complaining of shortness of breath, fatigue, and weakness, who was found to have significantly increased leukocytosis, hepatosplenomegaly, and was negative for the Ph chromosome. Further investigations with NGS revealed mutations in ASXL1, GATA2, NRAS, and SRSF2 but not CSF3R. In addition to this, peripheral smear and bone marrow aspiration findings were suggestive of aCML based on specific morphological findings. Since the patient was ineligible for a stem cell transplant (SCT), symptomatic treatment was started with cell transfusion; however, the patient continued to have symptomatic anemia that required multiple transfusions. A trial with trametinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, was later started as a targeted therapy based on one of her genetic mutations. Interestingly, the patient's blood counts stabilized, she reported feeling better, and she did not need any blood transfusions for four consecutive months during treatment with trametinib. Unfortunately, our patient later died from sepsis resulting from secondary infections. In light of the significant advancements in NGS, clinicians should always consider utilizing it as a helpful tool to not only establish a rare diagnosis of aCML but also to offer the best available targeted therapy when applicable. This might alleviate the burden associated with the poor prognosis of aCML.
引用
收藏
页数:8
相关论文
共 43 条
  • [1] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert
    Thiele, Jurgen
    Borowitz, Michael J.
    Le Beau, Michelle M.
    Bloomfield, Clara D.
    Cazzola, Mario
    Vardiman, James W.
    [J]. BLOOD, 2016, 127 (20) : 2391 - 2405
  • [2] A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms
    Assi, Rita
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Wang, Xuemei
    Nogueras-Gonzalez, Graciela
    Jabbour, Elias
    Bose, Prithviraj
    Kadia, Tapan
    Dinardo, Courtney D.
    Patel, Keyur
    Bueso-Ramos, Carlos
    Zhou, Lingsha
    Pierce, Sherry
    Gergis, Romany
    Tuttle, Carla
    Borthakur, Gautam
    Estrov, Zeev
    Luthra, Rajyalakshmi
    Hidalgo-Lopez, Juliana
    Verstovsek, Srdan
    Daver, Naval
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (02) : 277 - 285
  • [3] Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies
    Borthakur, Gautam
    Popplewell, Leslie
    Boyiadzis, Michael
    Foran, James
    Platzbecker, Uwe
    Vey, Norbert
    Walter, Roland B.
    Olin, Rebecca
    Raza, Azra
    Giagounidis, Aristoteles
    Al-Kali, Aref
    Jabbour, Elias
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Bauman, John W.
    Wu, Yuehui
    Liu, Yuan
    Schramek, Dan
    Cox, Donna S.
    Wissel, Paul
    Kantarjian, Hagop
    [J]. CANCER, 2016, 122 (12) : 1871 - 1879
  • [4] Breccia M, 2006, HAEMATOLOGICA, V91, P1566
  • [5] Preclinical efficacy of MEK inhibition in Nras-mutant AML
    Burgess, Michael R.
    Hwang, Eugene
    Firestone, Ari J.
    Huang, Tannie
    Xu, Jin
    Zuber, Johannes
    Bohin, Natacha
    Wen, Tiffany
    Kogan, Scott C.
    Haigis, Kevin M.
    Sampath, Deepak
    Lowe, Scott
    Shannon, Kevin
    Li, Qing
    [J]. BLOOD, 2014, 124 (26) : 3947 - 3955
  • [6] Atypical Chronic Myeloid Leukemia: Where Are We Now?
    Crisa, Elena
    Nicolosi, Maura
    Ferri, Valentina
    Favini, Chiara
    Gaidano, Gianluca
    Patriarca, Andrea
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (18) : 1 - 17
  • [7] SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias
    Damm, F.
    Itzykson, R.
    Kosmider, O.
    Droin, N.
    Renneville, A.
    Chesnais, V.
    Gelsi-Boyer, V.
    de Botton, S.
    Vey, N.
    Preudhomme, C.
    Clavert, A.
    Delabesse, E.
    Park, S.
    Birnbaum, D.
    Fontenay, M.
    Bernard, O. A.
    Solary, E.
    [J]. LEUKEMIA, 2013, 27 (06) : 1401 - 1403
  • [8] What's different about atypical CML and chronic neutrophilic leukemia?
    Dao, Kim-Hien T.
    Tyner, Jeffrey W.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 264 - 271
  • [9] Atypical chronic myeloid leukemia: a rare entity with management challenges
    Dhakal, Prajwal
    Gundabolu, Krishna
    Amador, Catalina
    Rayamajhi, Supratik
    Bhatt, Vijaya Raj
    [J]. FUTURE ONCOLOGY, 2018, 14 (02) : 177 - 185
  • [10] Atypical chronic myeloid leukaemia - a rare subtype of myelodysplastic/myeloproliferative neoplasm
    Drozd-Sokolowska, Joanna E.
    Waszczuk-Gajda, Anna
    Madry, Krzysztof
    Dwilewicz-Trojaczek, Jadwiga
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2018, 22 (01): : 14 - 19